Showing 1 posts of 1 posts found.
July 31, 2024 Media Relations, Medical Communications, Pharmacovigilance, US Healthcare & Trade Press FDA, Gastrointestinal tract, compunded injectable, dosage, hospitalisation, pharmaceutical, warning
Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial
Highlighting the value of lab research for healthcare innovation
Capital Dynamics invests €14m in Italian community healthcare platform CareHub
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO